The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Oncology Molecular Diagnostics Market Be By 2030 Compared To Its 2026 Market Size?
The oncology molecular diagnostics market size has experienced rapid growth in recent years. This market is set to expand from $5.65 billion in 2025 to $6.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.2%. Historically, this expansion has been driven by increasing cancer prevalence, the adoption of PCR and sequencing, substantial oncology research funding, the expansion of hospital diagnostic capabilities, and regulatory approvals for various molecular tests.
The oncology molecular diagnostics market is anticipated to experience significant expansion over the next few years. It is projected to achieve a size of $10.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.4%. This growth during the forecast period can be attributed to factors such as the adoption of precision oncology, advancements in liquid biopsy, the demand for personalized treatment solutions, AI-driven data interpretation, and the penetration into emerging markets. Major trends for the upcoming period include the rise of companion diagnostics, increased utilization of liquid biopsy, the expansion of biomarker-based testing, growing cancer screening programs, and a sustained demand for early and accurate cancer detection.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Oncology Molecular Diagnostics Market?
The future expansion of the oncology molecular diagnostics market is anticipated due to the rising need for personalized medicine. This innovative healthcare method involves customizing medical decisions, treatment practices, interventions, and drug therapies specifically for each patient. For cancer patients, oncology molecular diagnostics play a crucial role in personalized medicine, facilitating tailored treatment plans, optimal drug choices, and more accurate, potent, and unique treatment approaches, which ultimately enhance patient results and overall quality of life. An illustration of this trend is seen in a February 2024 report by the Personalized Medicine Coalition, a US-based nonprofit organization, which stated that the FDA granted approval to 16 novel personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the growth of the oncology molecular diagnostics market.
Which Segment Classifications Are Used In The Oncology Molecular Diagnostics Market Segment Analysis?
The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing
What Trends Are Shaping The Future Of The Oncology Molecular Diagnostics Market?
Major companies within the oncology molecular diagnostics market are prioritizing advancements in genomics technologies, such as next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling, to enhance early cancer detection, mutation identification, and personalized treatment approaches. These improvements increase diagnostic accuracy, shorten processing times, and cater to the escalating need for localized, highly precise molecular testing. For example, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider specializing in genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, opened a state-of-the-art laboratory at Burjeel Medical City in the UAE. This facility, a result of collaboration between Burjeel Holdings and OncoHelix, reinforces regional diagnostic capabilities by enabling complex molecular and immunology tests to be performed locally instead of being sent overseas. Its specialized services include advanced assays for multiple cancers, such as prostate cancer, supported by partnerships like its agreement with Nanostics for the ClarityDX Prostate test.
Which Firms Are Contributing To The Oncology Molecular Diagnostics Market Ecosystem?
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
Get The Full Oncology Molecular Diagnostics Market Report:
Which Region Leads The Oncology Molecular Diagnostics Market In Terms Of Market Share?
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Oncology Molecular Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Oncology Molecular Diagnostics Market 2026, By The Business Research Company
Diagnostic Imaging Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-imaging-equipment-global-market-report
Diagnostic And Monitoring Ophthalmic Devices And Equipment Market Report 2026
Microbiology Diagnostic Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
